This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Chronic Hepatitis C Infection
and you are
between 18 and 70
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The primary objective of this protocol is to study the effect of the standard of care in hepatitis C (pegylated interferon and ribavirin) associated with therapeutic vaccine TG4040 on the viral load of treatment-naïve patients with chronic genotype 1 hepatitis C infection.

Provided treatments

  • Drug: pegylated interferon and ribavirin
  • Biological: TG4040 + SOC
  • Biological: TG4040 + SOC

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01055821. The sponsor of the trial is Transgene and it is looking for 140 volunteers for the current phase.
Official trial title:
A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naïve Patients With Chronic Genotype 1 Hepatitis C.